0

THE HIGHEST CONTENT OF FURANODIENES ON THE MARKET

The extraction technique developed by Biosfered allows to obtain an extract with a high percentage of furanodienes in gas- chromatographic analyses. The use of an internal standard allows the precise quantification of furanodienes that are expressed on the weight of the finished product (with concentrations > 40 g/Kg).

READ SOME MYRLIQ® FACTS

> QUANTITATIVE DETERMINATION OF FURANODIENES
> ANALGESIC PROPERTIES OF MYRLIQ®: CLINICAL TRIALS
> MECHANISM OF ACTION AND EFFICACY OF MYRLIQ®
> OTHER CLINICAL STUDIES WITH MYRLIQ®
GO TO PAGE

Powder extract

Myrrh extract powder obtained at low temperature by a patented process from Biosfered (TO2014A000084) that preserves all the properties of the original raw material.

Fluid extract

It is the only source of liquid extract of myrrh resin-gums on the market.
It is free of ethanol and offers a unique set of commercial applications.

Myrliq possesses four main activities

ANALGESIC

ANALGESIC

Studies conducted on myrrh furanodienes demonstrated that furaneudesma-1 ,3-diene and curzerene have analgesic activity due to their interaction with opioid receptors of the central nervous system.

ANESTHETIC

ANESTHETIC

Furanodienes such as the furanodiene-6-one and metoxyfuranoguaia-9-ene-8-one, show local-anesthetic properties due to the selective and reversible block of sodium channels.

ANTIMICROBIC

ANTIMICROBIC

Furanodiene-6-one and metossifuranoguaia-9-ene-8-one, at concentrations ranging from 0.18 to 2.8 mg / ml, have activity towards pathogens such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans.

ANTINFLAMMATORY

ANTINFLAMMATORY

The myrrh extract inhibits the production of IL-6 and IL-8 in cells of human gingival fibroblasts; block proteins involved in the inflammatory process such as Cox; inhibits the formation of NO, ROS, TNF-α, PGE2, NF-kB and MAPK. Clinical studies indicate that the extract of myrrh induces significant improvements of osteoarthritis.